Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
86 GBX | -9.47% | -14.00% | -25.22% |
05-23 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
05-23 | Celadon Pharmaceuticals plc Announces Supply of Products to New US Customer | CI |
Sales 2021 | - | Sales 2022 | 0.02 0.03 | Capitalization | 31.14M 42.39M |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | -17M -23.14M | EV / Sales 2021 * | - |
Net cash position 2021 | 4.46M 6.08M | Net cash position 2022 | 429K 584K | EV / Sales 2022 | 1,279,759,792 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.71
x | Employees | 24 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 34.5% |
1 day | -9.47% | ||
1 week | -14.00% | ||
1 month | -15.27% | ||
3 months | -14.00% | ||
6 months | -14.00% | ||
Current year | -25.22% |
Managers | Title | Age | Since |
---|---|---|---|
James Short
FOU | Founder | 55 | 17-12-31 |
Jonathan Turner
DFI | Director of Finance/CFO | 46 | 23-01-16 |
Iqbal Gill
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Firth
BRD | Director/Board Member | 62 | - |
Ian Anton
CHM | Chairman | 64 | 22-03-27 |
Robert Barr
BRD | Director/Board Member | 65 | 22-03-27 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 86 | -9.47% | 226,466 |
24-05-30 | 95 | +2.70% | 61,090 |
24-05-29 | 92.5 | -.--% | 13,723 |
24-05-28 | 92.5 | -7.50% | 29,889 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am
More quotes1st Jan change | Capi. | |
---|---|---|
-25.22% | 71.94M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- CEL Stock